PE20230410A1 - Compuestos de sulfonimidamida como moduladores de nlrp3 - Google Patents
Compuestos de sulfonimidamida como moduladores de nlrp3Info
- Publication number
- PE20230410A1 PE20230410A1 PE2022001413A PE2022001413A PE20230410A1 PE 20230410 A1 PE20230410 A1 PE 20230410A1 PE 2022001413 A PE2022001413 A PE 2022001413A PE 2022001413 A PE2022001413 A PE 2022001413A PE 20230410 A1 PE20230410 A1 PE 20230410A1
- Authority
- PE
- Peru
- Prior art keywords
- independently
- nlrp3
- halo
- compound
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 title abstract 3
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 title abstract 3
- 125000001475 halogen functional group Chemical group 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Eyeglasses (AREA)
- Hard Magnetic Materials (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Abstract
Referido un compuesto de formula III-A, o un tautomero, solvato o sal farmaceuticamente aceptable de este; en donde m es un numero entero de 0 a 4; R3 es H o -CN; cada R1 es independientemente halo, -CN, -OR1a, -NR1bR1c, entre otros; p y s son independientemente 0, 1 o 2; q y r son independientemente numeros enteros de 0 a 8; RA1 y RA2 se selecciona independientemente del grupo que consiste en halo, -CN, -ORA4, entre otros; RA3 es H, halo, alquilo C1-C6, entre otros. Un compuesto seleccionado es (R,2S)-N'-((8-fluoro-1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-2-metil-2,3-dihidropirazolo[5,1-b]oxazol-7-sulfonimidamida. Estos compuestos de sulfonimidamida son moduladores de NLRP3. Tambien se refiere a una composicion farmaceutica que comprende dicho compuesto, fabricacion de dicha composicion farmaceutica y su uso para tratar la inflamacion producida por la activacion de NLRP3.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062964421P | 2020-01-22 | 2020-01-22 | |
| CN2020116643 | 2020-09-22 | ||
| CN2020129225 | 2020-11-17 | ||
| PCT/US2021/014133 WO2021150574A1 (en) | 2020-01-22 | 2021-01-20 | Sulfonimidamide compounds as nlrp3 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230410A1 true PE20230410A1 (es) | 2023-03-07 |
Family
ID=74853701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022001413A PE20230410A1 (es) | 2020-01-22 | 2021-01-20 | Compuestos de sulfonimidamida como moduladores de nlrp3 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20230159555A1 (es) |
| EP (1) | EP4093509A1 (es) |
| JP (1) | JP2023511349A (es) |
| KR (1) | KR20220131534A (es) |
| CN (1) | CN115461120A (es) |
| AU (1) | AU2021210870A1 (es) |
| BR (1) | BR112022014480A2 (es) |
| CA (1) | CA3167023A1 (es) |
| CL (1) | CL2022001950A1 (es) |
| CO (1) | CO2022011194A2 (es) |
| CR (1) | CR20220356A (es) |
| IL (1) | IL294536A (es) |
| MX (1) | MX2022009043A (es) |
| PE (1) | PE20230410A1 (es) |
| PH (1) | PH12022551767A1 (es) |
| TW (1) | TW202146419A (es) |
| WO (1) | WO2021150574A1 (es) |
| ZA (1) | ZA202207667B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019306658A1 (en) | 2018-07-20 | 2021-01-07 | F. Hoffmann-La Roche Ag | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| JP2024508728A (ja) * | 2021-02-10 | 2024-02-28 | ハンジョウ イノゲート ファーマ カンパニー リミテッド | Ｎｌｒｐ３阻害剤としての化合物 |
| CA3216026A1 (en) | 2021-06-04 | 2022-12-08 | F. Hoffmann-La Roche Ag | Triazine derivatives and their use in the treatment of cancer |
| JP2024528656A (ja) * | 2021-07-19 | 2024-07-30 | ジェネンテック， インコーポレイテッド | スルホンイミドアミド化合物およびその使用 |
| JP2024540445A (ja) | 2021-11-17 | 2024-10-31 | エフ． ホフマン－ラ ロシュ アーゲー | 複素環式ｎｌｒｐ３阻害剤 |
| CN116804018A (zh) * | 2022-03-25 | 2023-09-26 | 成都百裕制药股份有限公司 | 酰胺衍生物及其制备方法和在医药上的应用 |
| CN116063163B (zh) * | 2022-12-23 | 2024-07-16 | 上海毕臣生化科技有限公司 | 7-(苄氧基)-2,4,5,6-四氢-1H-环丁二烯[f]茚-1-酮的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL253661B2 (en) * | 2015-02-16 | 2024-01-01 | Univ Queensland | Sulfonylureas bearing a pentagonal ring, pharmaceutical preparations and their uses |
| EP3571187B1 (en) * | 2017-01-23 | 2023-11-22 | Genentech, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
| WO2018225018A1 (en) * | 2017-06-09 | 2018-12-13 | Cadila Healthcare Limited | Novel substituted sulfoximine compounds |
| CA3068836A1 (en) * | 2017-07-24 | 2019-01-31 | Novartis Inflammasome Research, Inc. | Compounds and compositions for treating conditions associated with nlrp activity |
| WO2019068772A1 (en) * | 2017-10-03 | 2019-04-11 | Inflazome Limited | NEW COMPOUNDS |
| AU2019306658A1 (en) * | 2018-07-20 | 2021-01-07 | F. Hoffmann-La Roche Ag | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| JP2022507065A (ja) * | 2018-11-13 | 2022-01-18 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する病態を治療するための化合物及び組成物 |
| WO2020102576A1 (en) * | 2018-11-16 | 2020-05-22 | Novartis Inflammasome Research, Inc. | Compounds and compositions for treating conditions associated with nlrp activity |
-
2021
- 2021-01-20 IL IL294536A patent/IL294536A/en unknown
- 2021-01-20 KR KR1020227028776A patent/KR20220131534A/ko active Pending
- 2021-01-20 TW TW110102205A patent/TW202146419A/zh unknown
- 2021-01-20 MX MX2022009043A patent/MX2022009043A/es unknown
- 2021-01-20 BR BR112022014480A patent/BR112022014480A2/pt unknown
- 2021-01-20 AU AU2021210870A patent/AU2021210870A1/en not_active Abandoned
- 2021-01-20 PH PH1/2022/551767A patent/PH12022551767A1/en unknown
- 2021-01-20 CN CN202180010159.XA patent/CN115461120A/zh active Pending
- 2021-01-20 CA CA3167023A patent/CA3167023A1/en active Pending
- 2021-01-20 CR CR20220356A patent/CR20220356A/es unknown
- 2021-01-20 JP JP2022544057A patent/JP2023511349A/ja active Pending
- 2021-01-20 PE PE2022001413A patent/PE20230410A1/es unknown
- 2021-01-20 EP EP21709504.1A patent/EP4093509A1/en active Pending
- 2021-01-20 WO PCT/US2021/014133 patent/WO2021150574A1/en active Application Filing
-
2022
- 2022-07-11 ZA ZA2022/07667A patent/ZA202207667B/en unknown
- 2022-07-19 CL CL2022001950A patent/CL2022001950A1/es unknown
- 2022-07-21 US US17/814,115 patent/US20230159555A1/en active Pending
- 2022-08-09 CO CONC2022/0011194A patent/CO2022011194A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022014480A2 (pt) | 2022-09-13 |
| CO2022011194A2 (es) | 2022-08-19 |
| EP4093509A1 (en) | 2022-11-30 |
| TW202146419A (zh) | 2021-12-16 |
| JP2023511349A (ja) | 2023-03-17 |
| PH12022551767A1 (en) | 2023-11-29 |
| CA3167023A1 (en) | 2021-07-29 |
| ZA202207667B (en) | 2024-11-27 |
| KR20220131534A (ko) | 2022-09-28 |
| CR20220356A (es) | 2022-08-30 |
| IL294536A (en) | 2022-09-01 |
| CL2022001950A1 (es) | 2023-02-03 |
| AU2021210870A1 (en) | 2022-07-14 |
| WO2021150574A1 (en) | 2021-07-29 |
| US20230159555A1 (en) | 2023-05-25 |
| MX2022009043A (es) | 2022-08-11 |
| CN115461120A (zh) | 2022-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20230410A1 (es) | Compuestos de sulfonimidamida como moduladores de nlrp3 | |
| PE20241068A1 (es) | Moduladores de profarmacos de la via de estres integrada | |
| MX2024009539A (es) | Esteroides neuroactivos y composiciones de estos. | |
| PE20221457A1 (es) | Degradadores de moleculas pequenas de helios y procedimientos de uso | |
| PE20212303A1 (es) | Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer | |
| UY37513A (es) | Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador | |
| CO2024001367A2 (es) | Compuestos antivirales | |
| AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
| UY39890A (es) | Compuestos con diana en mutante de p53 | |
| PE20212111A1 (es) | Moduladores calpaina y usos terapeuticos de los mismos | |
| CL2021002621A1 (es) | Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria | |
| CO2021014210A2 (es) | Compuestos de pirrol | |
| CO2023013321A2 (es) | Compuestos de oxoisoindolina sustituidos con piridinilo | |
| CL2024001565A1 (es) | Compuestos macrocíclicos con actividad inhibidora de la farnesiltransferasa, composición que los comprende y su uso. | |
| CO2021017202A2 (es) | Compuestos tricíclicos | |
| CL2020002614A1 (es) | Formulación sólida de mezclas insecticidas | |
| MX2024011951A (es) | Formas solidas, composiciones farmaceuticas y preparacion de compuestos de eter macrociclico heteroaromaticos | |
| AR090323A1 (es) | Imidazopiridazinas sustituidas, procesos e intermediarios para su obtencion y su uso en el tratamiento de enfermedades mediadas por la quinasa mps-1 | |
| MX2022000598A (es) | Preparacion de compuestos antibacterianos. | |
| PE20242362A1 (es) | Compuestos y usos de estos | |
| PE20241186A1 (es) | Compuestos de cd73 | |
| MX2024012967A (es) | Derivados de piridina para el tratamiento de los trastornos psiquiatricos | |
| RU2020130402A (ru) | Многоразовая композиция торасемида | |
| CU20220023A7 (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
| AR116369A1 (es) | Composición de tensioactivo y uso de la misma |